ATLANTA--(BUSINESS WIRE)--Capsalus Corp. (OTCBB:WELL), a public company operating in the health and wellness space, has finalized the definitive agreement with leading biosciences company GeneLink Biosciences, Inc. (OTCBB:GNLK) to acquire 100% of the stock of its wholly owned direct-selling subsidiary GeneWize Life Sciences, Inc., pending GeneLink shareholder approval and other related terms. The deal, Capsalus’ third in less than a year, will provide immediate revenues.